Journal
NEW BIOTECHNOLOGY
Volume 30, Issue 3, Pages 319-326Publisher
ELSEVIER
DOI: 10.1016/j.nbt.2012.11.011
Keywords
-
Funding
- Operational Programme Italy-Slovenia (project GLIOMA)
Ask authors/readers for more resources
Biomarkers are indicators of a specific biological state. Their detection in pathological conditions, such as cancer, is important for clinical disease management. One of their greatest values could be in early diagnosis and detection of neoplasms when the cancer is more manageable. Protein biomarkers are expected to be reliable predictors of pathological conditions, as they represent the endpoint of biological processes. The proteomic methodology has rapidly evolved in the past ten years, thus enabling discovery of a vast amount of potential biomarker candidates. However, the majority of novel candidates have not yet reached the integration into clinical environment. To do that, well-constructed large population validation studies are necessary as well as development of new algorithms for deciphering complex biological interactions and their involvement in pathological processes. This review focuses on advances in classical proteomic approaches and emerging high-throughput proteomic technologies for identifying cancer biomarkers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available